Navigation Links
An Open Letter to Parents, Students, School Administrators, & Health Care Officials from Soapopular(R)
Date:11/8/2007

emain effective longer, kill bacteria that alcohol cannot, and safer to use in any environment.

Most importantly, given that schools, universities, and licensed day care facilities throughout the country have been outright banning alcohol-based products due to their inherent dangers and noxious side effects, including skin irritations and risk of infection when exposed to open cuts, the current MRSA outbreak has created a dangerous conundrum for students, teachers, parents, and our communities.

The good news is that MRSA, and most other easily transmitted germs and viruses can be avoided with simple precautionary steps. The most essential include frequent hand washing with soap and water, and proper bandaging of cuts and abrasions. But when washing with soap and water isn't readily convenient, appropriate hand sanitizing products should be applied.

Alcohol-Free Hand Sanitizers -- The Popular Choice

Our product is called Soapopular(R); and includes a full line of independently tested, alcohol-free, rinse-free, and fragrance free foaming hand sanitizers. First introduced to the Canadian marketplace three years ago in conformance with strict medical and food compliant guidelines, Soapopular(R) is FDA-registered and now available throughout the US and worldwide.

We're passionate about the quality of our product, and we're determined that alcohol-free is the most logical and most pragmatic hand sanitizing alternative. We're ready to put our resources into your hands, and offer a national proposition.

-- We invite any official school administrator or licensed day care

facility to contact us via our website, or our toll free hotline and

receive complimentary case(s) of Soapopular(R) alcohol-free hand

sanitizer for use throughout your organization.*

-- We invite all proactive national corporations or local businesses to

work with us in sponsoring the delivery of dispenser-based hand'/>"/>

SOURCE Soapopular
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
3. Tone Deafness Explained, from the Harvard Health Letter
4. CEL-SCI Corporation Releases Letter to Shareholders
5. For Most, Good Oral Care Does More Than Antibiotics to Prevent Dental-Related Heart Problems, Reports the Harvard Heart Letter
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
9. University of Pennsylvania School of Medicine Study Shows Significant Differences in English- and Spanish-speakers Use of Oncology Websites
10. Cantel Medical Corp.s Crosstex Subsidiary Addresses School MRSA Concerns With SaniTyze(TM) Brand Hand Sanitizer and Sanitex(R) Surface Disinfecting Line of Products
11. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Ky. , Jan. 15, 2014  Manufacturers, suppliers ... must be able to protect their most important ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of ... it steadfastly remains one of the most litigious ...
(Date:1/15/2014)... 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ... System as a non-invasive, wireless continuous glucose monitoring system, ... Chairman and Interim CEO of Echo Therapeutics, will present ... Conference. Mr. Doman will make a ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... Inc.,(Nasdaq: MEDX ) today announced interim ... an investigational oncology immunotherapy, as monotherapy or ... castration,resistant prostate cancer (mCRPC). Data presented showed ... was clinically active and,generally well-tolerated. Preliminary evidence ...
... and REGENSBURG, Germany, June 2 "A ... in recurrent or refractory anaplastic,astrocytoma suggests a ... commented Prof. Ulrich Bogdahn, Neuro-Oncologist and Coordinating,Investigator ... with AP,12009 in recurrent or refractory high-grade ...
Cached Medicine Technology:Interim Phase 1/2 Data of Ipilimumab in Prostate Cancer Presented at American Society of Clinical Oncology Annual Meeting 2Interim Phase 1/2 Data of Ipilimumab in Prostate Cancer Presented at American Society of Clinical Oncology Annual Meeting 3Interim Phase 1/2 Data of Ipilimumab in Prostate Cancer Presented at American Society of Clinical Oncology Annual Meeting 4Clinical Proof of Concept for TGF-beta 2-Inhibitor AP 12009 in Phase Iib EMEA provides Guidance on Phase III Design and Approval Requirements 2Clinical Proof of Concept for TGF-beta 2-Inhibitor AP 12009 in Phase Iib EMEA provides Guidance on Phase III Design and Approval Requirements 3Clinical Proof of Concept for TGF-beta 2-Inhibitor AP 12009 in Phase Iib EMEA provides Guidance on Phase III Design and Approval Requirements 4
(Date:4/17/2014)... 2014 Giving patients adrenaline after they suffer a cardiac ... prospects of surviving long-term, according to new research conducted ... patients who have a cardiac arrest get adrenaline, which ... for decades," said Dr. Steve Lin, an emergency physician ... advances in medical treatment, long-term survival rates of patients ...
(Date:4/17/2014)... LSTM have called for more research to be ... children in sub-Saharan Africa. In a paper in ... Russell Stothard, working with colleagues in the department ... University, in Cleveland Ohio, University of Cambridge and ... into the joint burden of HIV/AIDS and schistosomiasis ...
(Date:4/16/2014)... Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced today that final ... solid tumors, including long-term patient follow-up, have been published ... 232). The data demonstrate robust antibody and T cell ... very advanced cancers and suggest that CDX-1401 may predispose ...
(Date:4/16/2014)... it is well known that fertility treatments are the ... multiples are at elevated risk of premature birth, these ... Fertility and Sterility . The article identifies ... the odds of multiple births and prematurity, including expanding ...
(Date:4/15/2014)... , , CHAMPAIGN, Ill. Scientists have solved a decades-old medical mystery ... way to fight invasive fungal infections, which kill about 1.5 million ... of action of amphotericin, an antifungal drug that has been in ... nearly as toxic to human cells as it is to the ...
Breaking Medicine News(10 mins):Health News:Adrenaline does little to increase patient's survival after cardiac arrest 2Health News:More research called for into HIV and schistosomiasis coinfection in African children 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 4Health News:Preterm births, multiples, and fertility treatment 2Health News:Preterm births, multiples, and fertility treatment 3Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 3
... BMR, TORONTO, Dec. 12 /PRNewswire-FirstCall/ - Bradmer ... and,commercialization of cancer therapies, today announced that Keith ... to join the Company,s Scientific,Advisory Board. Dr. Black ... America, having performed more than 5,000 operations for ...
... Patient organizations support extending MSP and using savings ... American Kidney Fund and DaVita Patient Citizens submit ... WASHINGTON, Dec. 12 -Kidney Care Partners --,a ... manufacturers working together to improve quality of care ...
... Asia, Africa may not apply to patients in the ... Disappointing the hopes of researchers, new trials using a ... little or no benefit from the drugs. , "It ... lecturer in infectious diseases at the University of Malawi ...
... movies and TV shows make light of womens so-called ... or, conversely, to menopause. In fact, mood disorders are ... studies have found women are 1.5 to 3 times ... are men. , In a newly published study, ...
... Scient,x USA, an innovative,leader in the development and marketing ... today that Bryce T. IntVeld has,joined the Company as ... provide leadership and oversee the establishment and expansion,of sales ... delighted to have Bryce as a member of our ...
... WASHINGTON, Dec. 12 The Long Term Care,Pharmacy ... policy voice,for pharmacies which specifically serve nursing home ... its membership to include LTC pharmacy,companies that serve ... living in 47 states., "LTCPA represents highly ...
Cached Medicine News:Health News:Bradmer announces additions to Scientific Advisory Board 2Health News:Bradmer announces additions to Scientific Advisory Board 3Health News:Kidney Patient Organizations, Kidney Community Come Out in Support of Medicare Secondary Payer (MSP) Extension 2Health News:Kidney Patient Organizations, Kidney Community Come Out in Support of Medicare Secondary Payer (MSP) Extension 3Health News:Steroid Fails to Ease Meningitis in Trials 2Health News:Steroid Fails to Ease Meningitis in Trials 3Health News:Experts call for better research into link between women's hormones and mood disorders 2Health News:Scient'x USA Strengthens Leadership Team With Appointment of Bryce IntVeld as Vice President of Sales 2Health News:Long Term Care Pharmacy Alliance Expands Membership; Members Now Serve Most of the Nation's Nursing Home Residents 2
The Editors and Contributors are a virtual "Who's Who" in surgery, and they have prepared an outstanding program that provides expert advice on a full range of problems. Destined to be the "gold stan...
The First Aid for the Surgery Clerkship is designed to prepare for the surgery clerkship examination and provides clinical diagnosis and treatment of many of the problems seen by surgeons....
CURRENT Consult: Surgery brings you authoritative clinical answers on more than 360 surgically treated disorders in the most efficient format, perfectly devised for the busy physician....
... enable all those involved with healthcare decisions ... very latest evidence in their field of ... each year as the volume of evidence ... delivering the best single source available for ...
Medicine Products: